Outpatient Treatment with Anti-Coronavirus Immunoglobulin Trial
Phase 3
820
about 5 years
18+
22 sites in AZ, CA, CO +10
What this study is about
This trial is testing whether a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) is better than a placebo for adults who have recently been diagnosed with COVID-19 and do not need hospitalization. The goal is to see if hIVIG helps people recover faster and improve their symptoms compared to the placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Receive Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: All-cause hospitalization or death through 28 days., Healthcare Utilization at Follow-up
Infectious